目的观察苗药痛风停汤内服配合水晶膏外敷治疗急性痛风性关节炎的临床疗效。方法将60例患者随机分为治疗组和对照组各30例,治疗组口服痛风停汤,每日1剂,局部配合外敷水晶膏,每天1次;对照组口服双氯芬酸钠,每次75 mg,每天1次。5 d后比较治疗前后临床证候积分,10 d后比较实验室指标及不良反应发生情况。结果两组总有效率比较,差异有统计学意义(P〈0.05);两组治疗后第1天和治疗前、第3天和第1天、第5天和第3天比较,疼痛、压痛、红肿及关节功能分级差异均有统计学意义(P〈0.01);两组患者治疗前后各项指标比较,差异有统计学意义(P〈0.01),治疗组优于对照组(P〈0.01);治疗组不良反应发生率与对照组比较,差异有统计学意义(P〈0.01)。结论痛风停汤配合水晶膏外敷能改善急性痛风患者临床症状及实验室指标,具有较好的临床疗效。
Objective To observe the clinical efficacy of acute gouty arthritis treated with tongfengting decoction of Miao medicine and shuijing topical cream. Methods 60 cases were randomized into a treatment group and a control group,30 cases in each one. In the treatment group, tongfengting decoction was prescribed for oral administration, 1 bag a day. Additionally, shuijing topical cream was used, once a day. In the control group,diclofenac sodium was prescribed for oral administration,75mg each time,once a day. The clinical syndrome score was compared in 5 days after treatment with that before treatment. The laboratory indexes and the adverse reactions were compared in 10 days after treatment. Results The total effective rate was different significantly between two groups (P 〈 0.05 ). In comparison between the results on the 1 st day after treatment and those before treatment, between those on the 3rd day and those on the 1 st day, between those on the 5th day and those on the 3rd day, the grades of pain, tenderness, redness, swelling and joint function were all different significantly in statistics ( P 〈 0.01 ). The differences in the indexes before and after treatment for the patients in two groups were significant statistically (P 〈 0.01 ). The results in the treatment group were superior to those in the control group(P 〈 0.01 ). The incidence of adverse reactions in the treat- ment group was different significantly as compared with that in the control group(P 〈0. O1 ). Conclusion The therapy of tongfengting decoction and shuijing topical cream relieves the symptoms of acute gouty arthritis,improves the laboratory indexes and achieves the superior clinical ellicacy.